100 Years of Lewy Bodies - Where are we now?

One hundred years ago, Jacob Heinrich Lewy described intracellular eosinophilic inclusions in the brains of patients with „paralysis agitans“, commonly known as Parkinson’s disease1. Enormous progress has been made during the past decades in analysing the content and formation of Lewy bodies and their relation to neurodegenerative diseases.

This conference intends to gather researchers in the field of pathological alpha-synuclein aggregation to foster scientific exchange and discuss roadmaps to new therapies. Poster presentations are encouraged. Two poster prizes will be awarded. Three abstracts will be selected for oral contribution.

The conference venue is the „Psychiatrische Universitätsklinik der Universität München“ where Lewy made his seminal discovery while working in the laboratory of Alois Alzheimer.
+ show speakers and program
Kai Bötzel Opening remarks
Richard Dodel Heinrich Lewy - the discovery of Lewy bodies
Maria Grazia Spillantini The relevance of Lewy bodies in PD
Thomas Gasser Genetic triggers of α-synuclein pathology in neurodegenerative diseases
Donato Di Monte Enviromental triggers of α-synuclein pathology in neurodegenerative diseases
Leonidas Stefanis Mechanisms of α-synuclein degradation
Vladimir Uversky
α-synuclein aggregation: The biophysical perspective
Markus Zweckstetter Structure of α-synuclein in different assembly states
Jochen Weishaupt Regulation of α-synuclein interaction in the cell by posttranslational modifications
Hilal A. Lashuel Role of posttranslational modifications in the formation of Lewy bodies
and α-synuclein pathology
Christian Haass Inhibition of mitochondrial fusion by α-synuclein is rescued py PINK1, Parkin
and DJ-1
Armin Giese α-synuclein aggregation: a therapeutic target
Günter Höglinger Protection against α-synuclein-induced cell death
Eliezer Masliah Targetting α-synuclein by immunotherapy
Wolfgang Oertel Concluding remarks

15 Sep - 15 Sep 2012

meeting website